KNOTUS Co.Ltd (278650) - Total Assets
Based on the latest financial reports, KNOTUS Co.Ltd (278650) holds total assets worth ₩156.41 Billion KRW (≈ $106.00 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of KNOTUS Co.Ltd to assess the company's total reinvestment commitment from operating cash flow.
KNOTUS Co.Ltd - Total Assets Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of KNOTUS Co.Ltd to evaluate the quality of earnings relative to operating cash generation.
KNOTUS Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
KNOTUS Co.Ltd's total assets of ₩156.41 Billion consist of 37.1% current assets and 62.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩46.15 Billion | 0.0% |
| Accounts Receivable | ₩11.12 Billion | 6.6% |
| Inventory | ₩1.51 Billion | 0.9% |
| Property, Plant & Equipment | ₩52.09 Billion | 31.0% |
| Intangible Assets | ₩3.49 Billion | 2.1% |
| Goodwill | ₩6.49 Billion | 3.9% |
Asset Composition Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is KNOTUS Co.Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KNOTUS Co.Ltd's current assets represent 37.1% of total assets in 2024, a decrease from 44.3% in 2016.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 24.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 7.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 31.0% of total assets.
KNOTUS Co.Ltd Competitors by Total Assets
Key competitors of KNOTUS Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
KNOTUS Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 1.37 | 1.86 |
| Quick Ratio | 1.25 | 1.34 | 1.71 |
| Cash Ratio | 0.00 | 1.01 | 0.00 |
| Working Capital | ₩11.37 Billion | ₩16.69 Billion | ₩13.20 Billion |
KNOTUS Co.Ltd - Advanced Valuation Insights
This section examines the relationship between KNOTUS Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.0% |
| Total Assets | ₩168.33 Billion |
| Market Capitalization | $186.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values KNOTUS Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: KNOTUS Co.Ltd's assets decreased by 2.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual total assets of KNOTUS Co.Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩168.33 Billion ≈ $114.07 Million |
-1.97% |
| 2023-12-31 | ₩171.71 Billion ≈ $116.37 Million |
-0.27% |
| 2022-12-31 | ₩172.19 Billion ≈ $116.69 Million |
+81.97% |
| 2021-12-31 | ₩94.63 Billion ≈ $64.13 Million |
+27.50% |
| 2020-12-31 | ₩74.22 Billion ≈ $50.29 Million |
+20.62% |
| 2019-12-31 | ₩61.53 Billion ≈ $41.70 Million |
+40.67% |
| 2018-12-31 | ₩43.74 Billion ≈ $29.64 Million |
+33.68% |
| 2017-12-31 | ₩32.72 Billion ≈ $22.17 Million |
+67.56% |
| 2016-12-31 | ₩19.53 Billion ≈ $13.23 Million |
-- |
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more